2
ALL2
Guardant HealthYear
2
ALL1
20231
2022DEALS // DEV.
2
ALL1
Deals1
DevelopmentsCountry
2
ALL2
U.S.A2
ALL1
AnHeart Therapeutics1
Blueprint MedicinesTherapeutic Area
2
ALL2
OncologyStudy Phase
2
ALL1
Approved1
Phase IIDeal Type
1
ALL1
CollaborationProduct Type
2
ALL2
Small moleculeDosage Form
1
ALL1
TabletLead Product
2
ALL1
Osimertinib Mesylate1
TaletrectinibTarget
1
ALL1
EGFRLead Product(s) : Taletrectinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AnHeart Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Guardant Health and AnHeart Therapeutics will develop Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for AB-106 (taletrectinib) in Advanced or Metastatic ROS1-Positive NSCLC.
Brand Name : AB-106
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2023
Lead Product(s) : Taletrectinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AnHeart Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Blueprint Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line Tagrisso (osimertinib) treatment.
Brand Name : Tagrisso
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Blueprint Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?